{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:11:40Z","timestamp":1792951900852,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ijrobp.2023.07.037","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T01:56:46Z","timestamp":1691805406000},"page":"169-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01)"],"prefix":"10.1016","volume":"118","author":[{"given":"Tingting","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghai","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaosu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-3312","authenticated-orcid":false,"given":"Xueguan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.07.037_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clinic"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0003","first-page":"1","article-title":"Assessment of toxic effects and survival in treatment deescalation with radiotherapy versus transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: The ORATOR2 phase 2 randomized clinical trial","volume":"8","author":"Palma","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0004","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2022.3458","article-title":"Caution regarding assessment of toxic effects and survival in treatment de-escalation with radiotherapy vs transoral surgery for human papillomavirus-associated oropharyngeal cancer","volume":"8","author":"Virgilio","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaa184","article-title":"Precision radiotherapy: Reduction in radiation for oropharyngeal cancer in the 30 ROC trial","volume":"113","author":"Riaz","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0006","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0009","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1634\/theoncologist.2020-0303","article-title":"Optimizing treatment deescalation in head and neck cancer: current and future perspectives","volume":"26","author":"Rosenberg","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0011","doi-asserted-by":"crossref","first-page":"9175","DOI":"10.1002\/cam4.5656","article-title":"Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0012","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1002\/cam4.3339","article-title":"Human papillomavirus (HPV) in Chinese oropharyngeal squamous cell carcinoma (OPSCC): A strong predilection for the tonsil","volume":"9","author":"Xu","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0013","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.3300","article-title":"Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx\u2014ECOG-ACRIN Cancer Research Group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdy522","article-title":"OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","volume":"30","author":"Seiwert","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0016","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2019.11.021","article-title":"A phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for Deintensification (AVOID): Omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx","volume":"106","author":"Swisher-McClure","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0018","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijrobp.2022.05.047","article-title":"Long-term toxic effects, swallow function, and quality of life on MC1273: A phase 2 study of dose de-escalation for adjuvant chemoradiation in human papillomavirus-positive oropharyngeal cancer","volume":"114","author":"Price","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0019","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106248","article-title":"30-day morbidity and mortality after transoral robotic surgery for human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma: A retrospective analysis of two prospective adjuvant de-escalation trials (MC1273 & MC1675)","volume":"137","author":"Haller","year":"2023","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0021","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0022","first-page":"djv368","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5fluorouracil, \u00b1 docetaxel for larynx preservation","volume":"108","author":"Janoray","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0023","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdn752","article-title":"Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: Survival, surgery, and organ preservation","volume":"20","author":"Posner","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0024","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdr006","article-title":"Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial","volume":"22","author":"Posner","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0026","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oraloncology.2016.03.014","article-title":"Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11","volume":"57","author":"Ward","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0028","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jamaoncol.2021.6416","article-title":"Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus-associated oropharyngeal carcinoma treated with definitive chemoradiotherapy","volume":"8","author":"Tsai","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0029","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0030","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.07.037_bib0031","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1200\/JCO.2021.39.15_suppl.6011","article-title":"Nivolumab, nabpaclitaxel, and carboplatin followed by risk\/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial","volume":"39","author":"Rosenburg","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162307726X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162307726X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:08:27Z","timestamp":1759745307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162307726X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S036030162307726X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.07.037","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}